Bio tech company updates — 5/4/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech financing is heating up, with companies including D&D Pharmatech and Threebillion tapping zero-interest convertible bond markets for record sums as investors prioritize clinical momentum over coupon income. D&D Pharmatech alone raised 226.5 billion won ($166 million) in the largest single biotech CB deal of 2026, while combined zero-interest CB issuances by large conglomerates have topped 1.1 trillion won over the past six months.
Key Findings
- D&D Pharmatech issued 226.5 billion won ($166 million) in zero-interest convertible bonds (CBs), marking the largest single fundraising deal in the Korean biotech sector in 2026.
- Threebillion is among the Korean biotechs raising large funds through zero-interest CBs, with investors betting on clinical momentum and licensing-out potential over coupon income.
- Combined zero-interest CB issuances by large conglomerates over the past six months have reached a total of 1.1 trillion won.
Details
Zero-Interest CB Wave Reshapes Korean Biotech Financing
According to the Seoul Economic Daily, the Korean biotech sector is experiencing a surge in zero-interest convertible bond issuances, driven by an issuer-led market where investors are willing to forgo coupon income in exchange for exposure to high-momentum clinical pipelines and licensing-out potential.
The trend's most striking data point is D&D Pharmatech's 226.5 billion won ($166 million) CB issuance, described as the single largest biotech fundraising deal of the year. Threebillion is also cited as a notable participant in this financing wave. The report notes that over the past six months, zero-interest CB issuances across large conglomerates in the sector have cumulatively reached 1.1 trillion won, underscoring the breadth of investor appetite.
This financing mechanism reflects a broader shift in how Korean biotech companies are accessing capital: rather than competing on yield, issuers are leveraging their clinical pipelines and anticipated licensing deals to attract institutional investors willing to accept zero-coupon terms in exchange for equity upside.
Note: Other recent Korean biotech stories — including BIO KOREA 2026, Novo Holdings' 100 billion won investment commitment, and AstraZeneca Korea's AI-bio partnerships — were published before the 2026-05-02 freshness cutoff and are therefore excluded from this edition.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
